Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Through the COLA Study and Biobank the investigators hope to enable further identification of phenotype, endocrine, ethnic, and metabolic characteristics associated with menstrual cycle disturbances; and: the identification of genetic or other etiologic factors associated with cycle disturbances.
Population Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Inclusion criteria WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
WHO II
Within women with WHO II status, polycystic ovary syndrome (PCOS) is diagnosed when at least 2 of the following criteria are met:
WHO III
Exclusion criteria
Study parameters In order to determine the phenotype characteristics of women with cycle disturbances, and to allow for the identification of genetic factors associated with cycle disturbances, the following parameters will be obtained.
Participation in the COLA Biobank will consist of the additional withdrawal of two blood vials (one for DNA and one for serum sampling) obtained during the routine diagnostic procedure.
Relatives of the index patient:
When a familial tendency of the WHO status is suspected on the basis of family history of 1st and 2nd degree relatives, these relatives will be invited for participation of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WHO anovulation | WHO I, II. III anovulation. See inclusion criteria |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| hormonal classification | FSH, LH, Estradiol, Progesterone,Testosterone, Androstenedione, Sex hormone binding globulin (SHBG), Cortisol, TSH | within 6 weeks |
| metabolic profile | total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, insulin, glucose | within 6 weeks |
| ovarian reserve | anti mullerian hormone, FSH and antral follicle count. | within 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| autoimmunity in WHO 3- POI patients | antithyroid peroxidase, antiadrenal, antiparietal and antiovarian antibodies | within 3 months |
| bone density in WHO 3- POI patients | a dual-energy x-ray absorptiometry (DEXA) scan |
Not provided
Inclusion Criteria:
WHO I Hypogonadotropic hypoestrogenic status (previously: "hypothalamic amenorrhea")
WHO II
Within women with WHO II status, PCOS is diagnosed when at least 2 of the following criteria are met:
WHO III
Exclusion criteria: Exclusion criteria
Not provided
Not provided
Women with cycle disturbances are referred to the outpatient clinic specialized in cycle disturbances by 1st or 2nd line care providers for further diagnostic procedures.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bart CJ Fauser, professor | UMC Utrecht | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Medical Center Utrecht | Recruiting | Utrecht | 3508GA | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30590587 | Derived | Christ JP, Gunning MN, Meun C, Eijkemans MJC, van Rijn BB, Bonsel GJ, Laven JSE, Fauser BCJM. Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019 Mar 1;104(3):809-818. doi: 10.1210/jc.2018-01787. | |
| 29605405 | Derived | Christ JP, Gunning MN, Palla G, Eijkemans MJC, Lambalk CB, Laven JSE, Fauser BCJM. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency. Fertil Steril. 2018 Apr;109(4):594-600.e1. doi: 10.1016/j.fertnstert.2017.11.035. Epub 2018 Mar 28. |
| Label | URL |
|---|---|
| study information | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D000858 | Anovulation |
| ID | Term |
|---|---|
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
6 x 500 μL serum, 2 x 500 μL EDTAplasma en 3 x 900 μL celpellet
| within 3 months |
| genotype in WHO 3 POI patients | karotype, fragile X mental retardation 1 gene premutation carriership | within 3 months |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |